1. Introduction {#sec0005}
===============

Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and viral pneumonia in infants and young children worldwide [@bib0005]. A global incidence estimate for RSV-associated acute respiratory infections (ARI) in children \<5 years in 2005 suggests 33.8 million new episodes of RSV-associated ARI with at least 3.4 million episodes necessitating hospital admission [@bib0010]. An estimated 66,000--190,000 children died from RSV-associated ARI, and 99% of these deaths occurred in developing countries, though the Middle East was not considered due to paucity of published data [@bib0010]. Specifically, very few population-based viral surveillance studies, including determining burden of RSV disease, have been performed in the Middle East, and few of these have used highly sensitive molecular techniques such as real-time reverse-transcriptase polymerase chain reaction [@bib0015], [@bib0020], [@bib0025], [@bib0030], [@bib0035], [@bib0040], [@bib0045], [@bib0050], [@bib0055], [@bib0060], [@bib0065]. Also, many of these studies had small samples sizes and the duration of the study period was usually for only one respiratory season. Thus, the true prevalence and burden of RSV disease in the Middle East remains unknown.

Recognizing that the viral etiology of ARI among Middle Eastern children in Arab countries was poorly characterized, in 2007 we had conducted a pilot viral surveillance study in children \<5 years admitted with respiratory symptoms and/or fever at two hospitals in Amman, Jordan over a three-month winter period [@bib0070], [@bib0075], [@bib0080]. Of the 728 subjects enrolled, \>80% tested positive for a virus by RT-PCR, with 64% testing positive for RSV. Compared to RSV-negative subjects, the RSV-positive subjects had lower median age, higher rates of oxygen use, longer hospital stay, and higher hospital charges. These pilot data suggested that in young hospitalized Jordanian children, the medical and financial burden of RSV was high. To more definitively address the burden of RSV disease in the present study, we conducted a three-year viral surveillance in Amman, Jordan and limited the age group to children \<2 years, the age group representing \>90% of the cases in our 2007 pilot study.

2. Methods {#sec0010}
==========

2.1. Study design {#sec0015}
-----------------

We conducted a prospective, year-round viral surveillance study enrolling children \<2 years with respiratory symptoms and/or fever within 48 h of hospital admission at Al-Bashir Hospital, the major government-run referral center in Amman, Jordan. Children were enrolled five days a week (Sunday through Thursday) if they presented with a history of fever and/or respiratory symptoms and one of the following admission diagnoses: ARI, apnea, asthma exacerbation, bronchiolitis, bronchopneumonia, croup, cystic fibrosis exacerbation, febrile seizure, fever without localizing signs, respiratory distress, pneumonia, pneumonitis, pertussis, pertussis-like cough, rule out sepsis, upper respiratory infection (URI), or other. Children were excluded only if they had chemotherapy-associated neutropenia and/or were newborns who had never been discharged.

Written informed consent was obtained from parents or guardians before enrollment into the study. The institutional review boards at the University of Jordan, the Jordanian Ministry of Health, and Vanderbilt University approved the study.

2.2. Study location {#sec0020}
-------------------

Al-Bashir Hospital is one of three major government-run referral medical centers that serve the population of Amman, which is estimated to be \>2 million. With its 185 pediatric beds (120 pediatric and 65 neonatal intensive care unit), the Ministry of Health estimates that during the study period, the Al-Bashir Hospital provided care for at least 50--60% of children in Amman (author SF, personal communication). Al-Bashir provides care to government employees and their dependents, underprivileged families in Amman, and patients who are referred from other health care centers in Jordan [@bib0085]. It is located in the low-income and densely populated Al-Ashrafieh area of eastern Amman, which includes the nearby Al Wihdat Palestinian refugee camp. Patients with financial constraints are also admitted to this hospital since Jordan adopted a policy of providing no-cost medical care to children \<6 years at government-run institutions regardless of insurance status. During the 3-year study period, there were 17,557 hospitalizations admitted to the pediatric wards, 11,230 (64%) among children \<2 years.

2.3. Data and specimen collection {#sec0025}
---------------------------------

Trained research staff obtained nasal and throat swabs from all enrolled children. If permission was granted, staff also obtained blood by a heel stick or venipuncture. Demographic characteristics and medical and social histories were obtained using standardized questionnaires; parents were queried in Arabic and the information was recorded in English. The medical charts were abstracted after discharge; demographic, epidemiologic, and clinical data were collected systematically. Vital signs at admission were recorded by clinicians. Oxygen saturations were collected as ranges:95--100%, 90--94%, 85--89%, and \<85%. Flaring or retractions were categorized as none, mild (flaring only), moderate (retractions), or severe (accessory muscle use). Wheezing on physical exam was categorized as none, end-expiratory, full expiratory or inspiratory, full expiratory and inspiratory, or not specified. Cyanosis was recorded as none, circumoral on crying only, circumoral at rest, generalized cyanosis at rest, or not specified. Documentation of microbiological data was obtained and viral identification laboratory results were recorded. Intensive care unit (ICU) stays included children who were either admitted directly to the ICU or were transferred in during the admission. Smoke exposure included both cigarette and/or nargalia (hookah pipe) exposure. Underlying conditions were collected and were categorized as the following: diabetes, heart disease, down\'s syndrome, kidney disease, sickle cell, cystic fibrosis, cancer, genetic/metabolic, cerebral palsy, neurological, mental retardation/developmental delay, seizure disorder, chronic diarrhea(e.g. \>2 weeks), gastroesophageal reflux disease, immunodeficiency, asthma/reactive airway disease, and liver disease. We entered data into a standardized, secured REDCap™ (Research Electronic Data Capture, Vanderbilt University, Nashville, TN, USA) database system [@bib0090]. Data quality checks were performed on at least 10% of the charts and all case report forms were verified after entry.

2.4. Classification {#sec0030}
-------------------

To better understand the role of RSV in pediatric lower respiratory tract infection (LRTI), we identified a sub-cohort of children. The LRTI cohort consisted of children with an admission diagnosis of asthma, bronchiolitis, bronchopneumonia, pneumonia, respiratory distress, or wheezing; or clinical signs of retractions or accessory muscle use; or wheezing on examination.

2.5. Laboratory testing {#sec0035}
-----------------------

Nasal and throat swabs were collected and combined in transport medium (M4RT^®^, Remel, USA), aliquoted into MagMAX™Lysis/Binding Solution Concentrate (Life Technologies, USA), snap frozen, and stored at −80 °C. Original and lysis buffer aliquots were shipped on dry ice and were tested by RT-PCR for eleven respiratory viruses (RSV, human metapneumovirus (HMPV), human rhinovirus (HRV), influenza (flu) A and B, C, and parainfluenza (PIV) virus 1, 2, and 3, adenovirus (adeno), and Middle East respiratory syndrome coronavirus (MERS-CoV) [@bib0095], [@bib0100], [@bib0105], [@bib0110], [@bib0115], [@bib0120], [@bib0125], [@bib0075], [@bib0130], [@bib0135].

2.6. Vitamin D testing {#sec0040}
----------------------

Blood was placed directly onto filter paper and air dried for ≥30 min before storage at room temperature and kept in a dry state until shipment to ZRT Laboratory (Beaverton, OR, USA) for vitamin D assay per protocol [@bib0140], [@bib0145], [@bib0150], [@bib0155], [@bib0160], [@bib0165].

2.7. Statistical analysis {#sec0045}
-------------------------

Descriptive statistics were presented as frequency (percentage) or median and interquartile range (IQR) where appropriate. Categorical variables were compared using Pearson Chi-square test. Continuous variables were compared using Mann-Whitney U test. For ≥3 groups comparison of continuous variables, Kruskal--Wallis test was used. We fit a multivariable logistic model to analyze the risk of oxygen use, ICU stay, mechanical ventilation, and length of stay as indicators for severity. The risk factors assessed included breastfeeding, vitamin D level, age at enrollment, gestational age, birth weight, gender, past medical history, smoke exposure, daycare, the four most common admission diagnoses (pneumonia, bronchopneumonia, bronchiolitis, and suspected sepsis) and RSV count. Daycare was removed from the ICU model because there were not subjects who were admitted to the ICU who attended daycare. All analyses were performed using statistical software R version 3.1.2 ([http://www.R-project.org/](http://www.r-project.org/){#intr0005}).

The enrolled sample was used to provide model-based estimates prevalence of RSV. The data were filtered to exclude admissions of individuals not residing in Amman. We used a Bayesian hierarchical model to derive prevalence estimates for each of the three years of the study [@bib0100]. In order to derive prevalence, estimates of the under 2-year-old Jordanian population were obtained from the World Bank online database, and the proportion of the population residing in Amman (35%) was taken from the 2012 national census [@bib0105]. These values were used in a binomial model to estimate the population of children \<2 years of age in Amman in 2010-2012. The market share for Al-Bashir hospital was modeled as a random variable, and given a uniform prior distribution between 50 and 60% of the market share. Finally, to account for the enrollment effort, the probability of enrollment was set to 71.4% (5 of 7 days) and used in a binomial model for the number enrolled in the study. Prevalence was given a diffuse beta (1,5) prior in all models. Each model was fitted using Markov chain Monte Carlo [@bib0110] methods as implemented in the PyMC 2.3 software package [@bib0115]. Models were run for 100,000 iterations, with the first 90,000 iterations conservatively discarded as burn-in. Models were checked for convergence using the Gelman-Rubin diagnostic [@bib0100] and for goodness of fit using posterior predictive checks [@bib0120].

3. Results {#sec0050}
==========

3.1. Study population {#sec0055}
---------------------

From March 16, 2010 to March 31, 2013, 3793 patients were eligible, of whom 3175 (83.7%) were enrolled. Seven patients (0.2%) were excluded: three were ≥2 years and four had the admission diagnosis of meningitis. Thus, 3168 subjects (83.5% of eligible subjects) were included in the final cohort.

3.2. Clinical and demographic characteristics of entire surveillance cohort {#sec0060}
---------------------------------------------------------------------------

The median age was 3.5 months (range 0.06--23.64 months), with 31% of the children \<2 month, 34% 2--5 months, 20% 6--11 months (total 85% \<1 year) and 15% 12--23 months. Sixty percent were male. Nearly 90% of the children had Jordanian parents, 7% Palestinian, and 3% other. By medical chart reviews or parent histories, 11.8% of the children were noted to have an underlying medical condition and 14% of the children had a history of prematurity (\<37 weeks). Prior to hospitalization, 41% received an antibiotic and nearly the entire cohort (92%) were administered an antibiotic during their hospital stay. Almost 93% of the children had one of five admission diagnoses: bronchopneumonia (32%), suspected sepsis (29%), bronchiolitis (17%), pneumonia (12%), and pertussis-like cough (7%). We had vitamin D levels for 2688 (85%) children; the median vitamin D level was 16.5 ng/mL.

3.3. Viral detection {#sec0065}
--------------------

All 3168 children had a nasopharyngeal swab obtained. A virus was detected in 81% of the children. The most common virus detected was RSV (44%), followed by HRV (39%), adeno (15%), HMPV (9%), PIV 1, 2, and 3 (6%), and Flu A, B and C(4%). MERS-CoV was not detected. [Fig. 1](#fig0005){ref-type="fig"} includes the frequency and distribution of RSV over a three-year period, with peaks in January and February. Of the 1397 RSV-positive children, 669 (48%) had at least one other virus detected and [Fig. 2](#fig0010){ref-type="fig"} illustrates the combination of these co-infections.Fig. 1The frequency of RSV-positive hospitalized children over the three-year study period (March 16, 2010 through March 31, 2013).Fig. 2The percent of RSV-positive only and RSV-positive with co-detection.

3.4. RSV hospitalization rates {#sec0070}
------------------------------

Using Jordanian census data and restricting our cohort to children who resided in Amman, we were able to estimate RSV hospitalization rates for each study year ([Table 1](#tbl0005){ref-type="table"} ). Of the 3168 children, 3048 (96.2%) resided in Amman. The RSV rates were substantially higher in children \<6 months (21.1--25.9 per 1000) compared to the older age groups: 6--8 per 1000 in 6--11-month-olds and 1.6--2.5 per 1000 in children ages 12--23 months.Table 1Estimated Rates of RSV Hospitalizations with 95% credible intervals by year and by age groups per 1000 persons.\<6 months6--11 months12--23 monthsYear 1 (03/16/2010--3/31/2011)21.1 (17.9, 24.4)6.8 (5.4, 8.4)1.6 (1.1, 2.1)Year 2 (04/01/2011--3/31/2012)23.5 (19.8, 26.8)6.0 (4.7, 7.5)2.3 (1.7, 2.9)Year 3 (04/01/2013--3/31/2013)25.9 (22.0, 29.4)8.0 (6.5, 9.9)2.5 (1.9, 3.2)

3.5. Clinical and demographic characteristics comparing RSV-positive to RSV-negative children {#sec0075}
---------------------------------------------------------------------------------------------

A comparison of RSV-positive children compared to RSV-negative is shown in [Table 2](#tbl0010){ref-type="table"} . RSV-positive children were more likely to have been previously healthy, with no significant underlying medical condition, and were less likely to be born prematurely ([Table 2](#tbl0010){ref-type="table"}). RSV-positive subjects were also more likely to have the diagnoses of bronchiolitis, bronchopneumonia, pneumonia, and pertussis-like cough compared to RSV-negative children ([Table 2](#tbl0010){ref-type="table"}). When comparing presenting symptoms as reported by parents, RSV-positive children were more likely to present with cough and shortness of breath and less likely to present with fever, decreased activity, diarrhea, or vomiting ([Table 2](#tbl0010){ref-type="table"}).Table 2Clinical and demographic comparisons of RSV-positive and RSV-negative children.Total *N* = 3168RSV-positive *N* = 1397RSV-negative *N* = 1771*p*-ValueAge (months) median3.5 months3.5 months0.16 0--1 months135 (10%)248 (14%)\<0.01 2--5 months736 (53%)772 (44%) 6--11 months327 (23%)394 (22%) 12--23 months199 (14%)357 (20%)Sex (male)834 (60%)1078 (61%)0.50Daycare[\*\*](#tblfn0070){ref-type="table-fn"}27 (2%)23 (1%)0.16Breastfeeding1200 (86%)1461 (82%)0.01No past medical history1286 (92%)1507 (85%)\<0.01Smoke exposure1070 (77%)1355 (77%)0.96Antibiotics prior to hospitalization653 (47%)633 (36%)\<0.01Antibiotics during hospitalization[a](#tblfn0005){ref-type="table-fn"}1279 (92%)1612 (92%)0.61Gestational\
 Age\
 Median % \< 37 weeks179 (13%)271 (15%)0.046Birth weight (median, kg)[•](#tblfn0075){ref-type="table-fn"}3.03.00.074**Admission diagnosis**Bronchiolitis374 (27%)173 (10%)\<0.01Bronchopneumonia476 (34%)544 (31%)0.045Pneumonia225 (16%)169 (10%)\<0.01Suspected sepsis248 (18%)664 (37%)\<0.01Pertussis-like cough129 (9%)96 (5%)\<0.01**Presenting symptoms**Fever649 (46%)1113 (63%)\<0.01Cough1320 (94%)1046 (59%)\<0.01Shortness of breath1039 (74%)793 (45%)\<0.01Runny nose/congestion40 (3%)37 (2%)0.16Decrease appetite301 (22%)399 (23%)0.51Seizures/convulsions19 (1%)106 (6%)\<0.01Decrease activity[\*](#tblfn0065){ref-type="table-fn"}77 (20%)238 (36%)\<0.01Diarrhea69 (5%)248 (14%)\<0.01Vomiting186 (13%)336 (19%)\<0.01**Key examination findings**Wheezing926 (66%)831 (47%)\<0.01Cyanosis362 (26%)258 (15%)\<0.01Flaring/retractions173 (12%)108 (6%)\<0.01Abnormal chest X-ray[b](#tblfn0010){ref-type="table-fn"}1122 (82%)955 (60%)\<0.01**Outcomes**O2 requirement[c](#tblfn0015){ref-type="table-fn"}566 (41%)447 (25%)\<0.01Days on oxygen (25th, 50th, 75th, mean, standard deviation)[▵](#tblfn0060){ref-type="table-fn"}1 2 5 (3.76 ± [3.3]{.ul})1 2 4 (3.28 ± [3.1]{.ul})0.041Mechanical ventilations[d](#tblfn0020){ref-type="table-fn"}52 (4%)59 (3%).54ICU stay[e](#tblfn0025){ref-type="table-fn"}126 (9%)158 (9%)0.89Median length of stay (days)[f](#tblfn0030){ref-type="table-fn"}440.2Death[d](#tblfn0020){ref-type="table-fn"}7 (0.5%)24 (1%)0.015Vitamin D level (ng/mL)[g](#tblfn0035){ref-type="table-fn"}14.3 ng/mL18.2 ng/mL\<0.01[^1][^2][^3][^4][^5][^6][^7][^8][^9][^10][^11]

The RSV-positive children were more likely to have a physician document wheezing, cyanosis, and abnormal flaring and retractions on exam and an abnormal chest radiograph ([Table 2](#tbl0010){ref-type="table"}). These children had a comparatively higher frequency of supplemental oxygen use, were more likely to have \<90% oxygen saturation at admission (9% vs. 6% for RSV-negative children, *p*  \< 0.01), and were less likely to have oxygen saturation \>95% (36% vs. 42%, *p*  \< 0.01). The RSV-positive children also had lower median vitamin D levels ([Table 2](#tbl0010){ref-type="table"}). The mortality rate was lower in the RSV-positive children, (0.5% vs. 1%, *p*  = 0.015). In order to understand if co-infection with another virus was associated with increased severity, we compared RSV-only children with RSV co-infected children. RSV-only children had slightly higher percentage of cough reported prior to admission 96% vs. 93% (*p*  \< 0.01), were more likely to report a runny nose/congestion (3% vs. 1%, *p*  = 0.01), and had comparable severity of disease.

3.6. Clinical characteristics of children with lower respiratory tract infection {#sec0080}
--------------------------------------------------------------------------------

In order to characterize the features of RSV-associated LRTI, we analyzed the subset of children who presented with LRTI. Of the 3168 children, 2263 (71.4%) met criteria for LRTI. Of these, 1210 (53.5%) had RSV, 785 (34.7%) had another virus detected, and 268 (11.8%) had no virus detected ([Table 3](#tbl0015){ref-type="table"} ). Children with RSV were more likely to be younger, have a history of breastfeeding, have the diagnoses of bronchiolitis or pertussis-like cough, present with cough or shortness of breath, and have cyanosis on exam compared to other virus-positive and virus-negative children ([Table 3](#tbl0015){ref-type="table"}). In addition, they were more likely to require oxygen and had lower median vitamin D levels ([Table 3](#tbl0015){ref-type="table"}). Children who had virus-negative LRTI were more likely to have an underlying medical condition, be admitted to the ICU, and die compared to the other groups ([Table 3](#tbl0015){ref-type="table"}).Table 3Clinical and demographic comparisons of lower respiratory tract infection by RSV-positive, other virus-positive, and virus-negative children.Total Cohort *N* = 2263RSV-positive LRTI (*N* = 1210)Virus other-positive LRTI (*N* = 785)Virus-negative LRTI (*n* = 268)*p*-ValueAge (months) median4.27.16.2\<0.01 0--1 months78 (6%)30 (4%)20 (7%)\<0.01 2--5 months618 (51%)249 (32%)92 (34%) 6--11 months320 (26%)279 (36%)76 (28%) 12--23 months194 (16%)227 (29%)80 (30%)Sex (male)733 (61%)484 (62%)154 (57%)0.48Daycare[a](#tblfn0040){ref-type="table-fn"}26 (2%)12 (2%)7 (3%)0.46Breastfeeding1031 (85%)627 (80%)211 (79%)0.002No past medical history1104 (91%)629 (80%)207 (77%)\<0.01Smoke exposure929 (77%)594 (76%)213 (79%)0.44Antibiotics prior to hospitalization605 (50%)371 (47%)128 (48%)0.46Antibiotics during hospitalization[b](#tblfn0045){ref-type="table-fn"}1099 (91%)708 (91%)236 88%)0.28Gestational\
 Age\
 Median % \< 37 weeks148 (12%)127 (16%)41 (15%)0.04Birth weight (kg)[c](#tblfn0050){ref-type="table-fn"} (25th, 50th, 75th, mean, standard deviation)2.6 3.0 3.5(3.0 ± 0.6)2.5 3.0 3.5(2.9 ± 0.7)2.5 3 3.4(2.9 ± 0.6)0.02**Admission Diagnosis**Bronchiolitis374 (31%)129 (16%)44 (16%)\<0.01Bronchopneumonia476 (39%)410 (52%)134 (50%)\<0.01Pneumonia225 (19%)126 (16%)43 (16%)0.28Suspected sepsis150 (12%)65 (8%)33 (12%)0.01Pertussis-like cough51 (4%)16 (2%)8 (3%)0.03**Presenting symptoms**Fever595 (49%)463 (59%)142 (53%)\<0.01Cough1176 (97%)685 (87%)205 (76%)\<0.01Shortness of breath964 (80%)545 (69%)175 (65%)\<0.01Runny nose/congestion38 (3%)17 (2%)9 (3%)0.38Decrease appetite234 (19%)95 (12%)47 (18%)\<0.01Seizures/convulsions8 (1%)19 (2%)9 (3%)\<0.01Decrease activity[d](#tblfn0055){ref-type="table-fn"}45 (16%)22 (12%)18 (20%)0.15Diarrhea58 (5%)63 (8%)17 (6%)0.01Vomiting149 (12%)97 (12%)41 (15%)0.39**Key examination findings**Cyanosis339 (28%)150 (19%)64 (24%)\<0.01Wheezing926 (77%)614 (78%)217 (81%)0.26Flaring173 (14%)73 (9%)35 (13%)0.08Abnormal x-ray[e](#tblfn0080){ref-type="table-fn"}1076 (90%)674 (89%)222 (84%)0.02**Outcomes**O~2~ requirement[f](#tblfn0085){ref-type="table-fn"}478 (40%)248 (32%)100 (38%)0.002Days on oxygen[g](#tblfn0090){ref-type="table-fn"} (25th, 50th, 75th, mean, standard deviation)1 2 5 (3.6 ± 3.3)1 2 4 (3.3 ± 3.1)1 2 3 (2.9 ± 3.1)0.042Mechanical ventilations[h](#tblfn0095){ref-type="table-fn"}48 (4%)31 (4%)15 (6%)0.46ICU stay[h](#tblfn0095){ref-type="table-fn"}107 (9%)63 (8%)40 (15%)0.003Median length of stay in days[i](#tblfn0100){ref-type="table-fn"} (25th, 50th, 75th, mean, standard deviation)2 3 6 (4.1 ± 3.3)1 3 6 (4.2 ± 4.7)1 3 6 (4.1 ± 4.3)0.05Death[h](#tblfn0095){ref-type="table-fn"}7 (0.6%)7 (0.9%)7 (3%)0.007Vitamin D level (ng/mL)[j](#tblfn0105){ref-type="table-fn"}15.120.320.5\<0.01[^12][^13][^14][^15][^16][^17][^18][^19][^20][^21]

3.7. Risk factors for illness severity: Oxygen use, ICU stay, mechanical ventilation, and length of stay {#sec0085}
--------------------------------------------------------------------------------------------------------

To assess for severity of illness indicators, we compared the following outcomes in RSV-positive children: oxygen requirement, any ICU stay, mechanical ventilation, and length of stay ([Table 4](#tbl0020){ref-type="table"}, [Table 5](#tbl0025){ref-type="table"} ) in a univariate and/or multivariable analyses. Lack of breastfeeding, lower age, and higher viral load (indicated by lower Ct values) were associated with oxygen use, while the diagnoses of bronchiolitis, suspected sepsis, and bronchopneumonia were not associated ([Table 4](#tbl0020){ref-type="table"}). The diagnoses of pneumonia and suspected sepsis and lower age were more likely to be associated with ICU stay but less likely with the diagnosis of bronchopneumonia ([Table 4](#tbl0020){ref-type="table"}). Mechanical ventilation was associated with younger age and higher vitamin D level ([Table 4](#tbl0020){ref-type="table"}). The following were associated with longer length of stay: having an underlying medical condition, lack of breastfeeding, the diagnoses of pneumonia and suspected sepsis, younger age, lower gestational age, and higher viral load (indicated by lower Ct values) in contrast, the diagnoses of bronchiolitis and bronchopneumonia were associated with shorter length of stay ([Table 5](#tbl0025){ref-type="table"}).Table 4Univariate and multivariable analysis of factors associated with oxygen use, ICU stay, and mechanical ventilation in RSV-positive children.Univariate analysisMultivariable analysis**Oxygen Use *N*** **=** **1382Oxygen *N*** **=** **566 (%)No oxygen *N*** **=** **816 (%)*****p*****-ValueAdjusted OR (95% CI)*****p*****-Value95% CI**Gender, male321 (57%)501 (61%)0.081.210.150.94--1.56Underlying medical condition44 (8%)63 (8%)0.971.540.090.93--2.53Daycare13 (2%)14 (2%)0.441.520.380.60--3.86Breastfeeding482 (85%)708 (87%)0.40**0.600.010.40--0.89**Smoke exposure428 (76%)631 (77%)0.461.140.390.85--1.53Vitamin D level (ng/mL)[a](#tblfn0110){ref-type="table-fn"} (25th, 50th, 75th, mean, standard deviation)2.9 10.7 23.6 (14.1 ± 12.4)4.6 15.8 26 (16.6 ± 12.5)\<0.010.890.670.69--1.15Gestational age (weeks) (25th, 50th, 75th, mean, standard deviation)38 40 40 (38.5± 2.3)38 40 40 (38.8± 2.2)0.020.900.300.71--1.14Median age, months \[IQR\]2.34.8\<0.01**0.26\<0.010.18--0.40**RSV ct count24.926.4\<0.01**0.72\<0.010.59--0.87**Birth Weight330.771.120.370.88--1.42Pneumonia128 (23%)96 (12%)\<0.011.460.060.98--2.18Bronchopneumonia126 (22%)342 (42%)\<0.01**0.650.040.43--0.98**Bronchiolitis151 (27%)221 (27%)0.87**0.640.030.43--0.98**Sepsis128 (23%)120 (15%)\<0.01**0.570.010.37--0.86**Univariate analysisMultivariable analysis**ICU Stay *N*** **=** **1381ICU Stay *N*** **=** **126 (%)No ICU Stay *N*** **=** **1255 (%)*****p*****-valueAdjusted OR (95% CI)*****p*****-value95% CI**Gender, male67 (53%)754 (60%)0.131.310.220.85--2.01Underlying medical condition12 (10%)94(7%)0.411.450.430.58--3.59Daycare0 (0%)27 (2%)0.10NANANABreastfeeding102 (81%)1087 (87%)0.080.550.080.28--1.07Smoke exposure93 (74%)965 (77%)0.441.010.980.61**--**1.67Vitamin D level (ng/mL)[b](#tblfn0115){ref-type="table-fn"}9.714.50.130.850.730.53**--**1.36Gestational age (weeks)3940\<0.010.760.060.50**--**1.15Median age (months) \[IQR\]1.53.7\<0.01**0.350.020.17--0.74**RSV ct count25.625.60.281.060.090.76--1.48Birth Weight330.080.880.550.59--1.33Pneumonia45 (36%)179 (14%)\<0.01**1.890.021.11--3.20**Bronchopneumonia12 (10%)456 (36%)\<0.01**0.380.030.16--0.90**Bronchiolitis22 (17%)350 (28%)0.010.700.310.36--1.38Sepsis59 (47%)189 (15%)\<0.01**1.810.041.02--3.21**Univariate analysisMultivariable analysis**Mechanical ventilation (MV) *N* = 1381MV *N*=** **52 (%)No MV *N*** **=** **1329 (%)*****p*****-valueAdjusted OR(95% CI)*****p*****-value95% CI**Gender, male29 (56%)792 (60%)0.581.090.780.61**--**1.95Underlying medical condition4 (8%)102 (8%)10.850.800.24--3.04Daycare2 (4%)25 (2%)0.323.090.150.66**--**14.52Breastfeeding45 (87%)1144 (86%)0.921.540.380.59--4.00Smoke exposure41 (79%)1017 (77%)0.70.720.370.35**--**1.49Vitamin D level (ng/mL)[b](#tblfn0115){ref-type="table-fn"}20.513.90.19**1.94**0.06**1.06--3.57**Gestational age (weeks)40400.580.870.210.50--1.50Median age, months \[IQR\]2.53.60.02**0.290.030.11--0.77**RSV ct count26.825.60.531.250.390.77--2.05Birth Weight3.0530.761.520.140.87--2.67Pneumonia14 (27%)210 (16%)0.031.830.160.78--4.28Bronchopneumonia13 (25%)455 (34%)0.171.040.940.38--2.81Bronchiolitis14 (27%)358 (27%)10.960.920.39--2.35Sepsis11 (21%)237 (18%)0.540.650.340.27--1.57[^22][^23]Table 5Multivariable analysis of Factors Associated with Length of Stay in RSV-Positive Children.Adjusted OR (95% CI)*p*-Value95% CIGender, male1.010.950.82--1.24Underlying medical condition**1.630.02**1.10--2.42Daycare1.570.240.73--3.34Breastfeeding**0.660.01**0.48--0.91Smoke exposure0.990.940.78--1.25Vitamin D level (ng/mL)0.970.640.78--1.19Gestational age (weeks)0.920.040.76--1.11Age\@Enrollment**0.39\<0.01**0.28--0.55RSV ct count**0.68\<0.01**0.58--0.80Birth Weight**0.870.16**0.71--1.05Pneumonia**1.77\<0.01**1.27--2.46Bronchopneumonia**0.710.04**0.51--0.99Bronchiolitis**0.57\<0.01**0.41--0.79Sepsis**2.08\<0.01**1.47--2.95

4. Discussion {#sec0090}
=============

In our 2010--2013 surveillance window, RSV was a major cause of ARI hospitalizations in Jordanian children \<2 years, with consistent annual peaks in January and February. Our study represents one of the largest cohort studies of RSV-infected hospitalized children, including within the Middle East [@bib0050], [@bib0055], [@bib0060], [@bib0065], [@bib0170], [@bib0175], [@bib0180], [@bib0185], [@bib0190], [@bib0195], [@bib0200], [@bib0205], [@bib0210], [@bib0215]. RSV is well-recognized cause of ARI globally [@bib0010], but even comprehensive reports typically fail to include information from the Middle East region due to lack of published data. Therefore, our study fills a knowledge gap of RSV burden in the Arab region.

Our estimates of hospitalized RSV incidence are consistent and even slightly higher than other estimates from developed and developing counties in which RT-PCR was used to calculate RSV-associated hospital rates. For instance, our estimated RSV-associated hospitalization rates in children \<6 months (range, 21--25 per 1000) were higher than a population-based study of three US hospitals that reported RSV-associated hospitalization rates for children \<6 months as averaging 17 per 1000 (range: 12.4--21.7) over a five-year period, in which 20% (564/2892) of the subjects were RSV-positive [@bib0220]. In a large population-based study of ARI in Egypt, of the 4993 children \<5 years of age in which a specimen was collected, 518 (11%) of the children were positive by RSV by RT-PCR, with the highest portion in the 1--11 months group (45%). They estimated RSV-associated hospitalized rates in children 1--11 months as 17.45 per 1000 [@bib0210]. Of note, they excluded children \<1 month of age, which most likely underestimated the burden of RSV. Other studies that estimated population-based RSV-associated hospital rates used less sensitive methods of RSV detection or only included children with children with severe ARI [@bib0225], [@bib0230], [@bib0235], [@bib0240], making comparisons challenging. Our study highlights the importance of active surveillance over longer study periods and the advantage of sensitive molecular RSV detection techniques to accurately estimate the true burden of RSV hospitalizations.

Not only are the hospitalization rates of RSV-positive children higher compared to RSV-negative, but the clinical characteristics are different and the severity of illness seems to be greater in these children [@bib0070], [@bib0220], [@bib0245], [@bib0250]. Prematurity and underlying medical conditions (e.g., heart or lung disease) are well-recognized risk factors for severe RSV [@bib0255]. However, the majority of our RSV-positive children were less likely to have been born prematurely or have an underlying medical condition compared to RSV-negative, consistent with other studies [@bib0170], [@bib0220]. In our cohort, RSV-positive children were more likely to be admitted with evidence of lower respiratory involvement (e.g., higher frequency of pneumonia, bronchiolitis and bronchopneumonia diagnoses and physical findings such as wheezing and retractions), present with hypoxemia and cyanosis, and require supplemental oxygen compared to RSV-negative children. Taken together, these results suggest that RSV is more likely to cause severe infection compared to other viruses.

Previously described risk factors associated with RSV hospitalization or severe illness include male sex, young age, birth in the first half of the RSV season, day care attendance, lack of breast feeding, chronic medical conditions, smoke exposure, and household crowding or siblings [@bib0220], [@bib0260], [@bib0265], [@bib0270], [@bib0275], [@bib0280], [@bib0285], [@bib0290]. Using oxygen use as on of the indicators for severity, our results are consistent with other reports finding a significant higher odds ratios for oxygen use in RSV-positive children with higher RSV viral load [@bib0295], [@bib0300], lack of breast feeding [@bib0305], and younger age [@bib0220]. When also evaluating for ICU stay, mechanical ventilation, and length of stay, underlying medical conditions [@bib0255] and the admission diagnoses of pneumonia and suspected sepsis were other risk factors identified. Environmental tobacco smoke exposure is a known risk factor for serious RSV disease [@bib0310]. However, nearly 3/4 of our children were exposed to smoke; this high exposure for the cohort may explain why smoke exposure was not identified as an independent risk factor. Low vitamin D levels and clinical rickets have been associated with pneumonia and severe ARI [@bib0315], [@bib0320], [@bib0325], [@bib0330]. Low vitamin D levels were associated with supplemental oxygen use in our univariate model; however, in the multivariable model it was no longer significant. Therefore, further investigation and public health interventions to reduce modifiable risk factors such as vitamin D supplementation, smoking cessation programs, and encouraging breastfeeding are needed in our population.

Prevention of RSV disease in young children may ultimately be possible with active immunization or maternal immunization, although no licensed RSV vaccine is currently available [@bib0335], [@bib0340]. The only preventive measure for RSV disease is palivizumab, an RSV monoclonal antibody, which reduces the risk of hospitalization caused by RSV in high-risk children [@bib0345]. Use of palivizumab is low in low and middle income countries due to the high cost of the drug. The vast majority of children hospitalized with RSV in our study were full term and previously healthy. Therefore, even if palivizumab were available widely in Jordan, only a few children would have been eligible and thus it would have little impact on overall RSV hospitalization rates. Other strategies to reduce RSV-associated hospitalization are needed, such as infant or maternal vaccination with future vaccines or antiviral therapies specific for RSV.

Our study is one of the largest prospective cohorts of Middle East children hospitalized for ARI. Moreover, each subject had molecular viral testing performed for 11 viruses and systematic data collection. However, our study does have some limitations. The administration of oxygen and other treatments was at the clinicians' discretion and we only collected oxygen saturations at admission, so data may not reflect truly serious disease. Nevertheless, RSV children were more likely to have lower saturation at admission compared to RSV-negative children, suggesting that RSV is associated with increased morbidity. We did not collect current steroid use, except for inhaled steroids, prior or during admission, which may have an effect on viral load and/or fever presentation*.* Chest radiograph findings were reported by clinicians and were not confirmed by independent radiologists. Children who were classified as virus-negative may have had other viral infections that we did not measure. Bacterial cultures were recorded when ordered by clinicians, but their reliability was uncertain because many infants received antibiotics before admission (over 40%) and the microbiology laboratory is not open for 24 h, delaying the processing of many specimens and therefore, we are not able to comment reliably about viral-bacterial co-infections. However, a recent prospective US study found that the majority of LRTI in hospitalized young children were caused by viral pathogens rather than bacteria (45). Since our RSV samples are not genotyped, we are unable to comment on differences in severity between RSV A and RSV B.

In conclusion, our three years of rigorous hospital surveillance confirm that RSV is a major cause of illness in young hospitalized Jordanian children. RSV is associated with increased severity compared to other respiratory viruses. Children in the Middle East would benefit from an RSV vaccine if one were available. In the meantime, public health policies directed at encouraging breastfeeding could be immediate interventions. RSV-specific chemotherapies are also needed. Future research on judicious use of antibiotics and the role of viral-bacterial co-detection are needed.
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